# Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

Study · id `cardio:ct-nct02407210` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02407210](<https://clinicaltrials.gov/study/NCT02407210>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02407210

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 304 participants.

## Technical summary

Registry record NCT02407210. Randomized; triple masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2015-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 304 participants (planned count; ClinicalTrials.gov record NCT02407210, source copy `cardio:ctgov-nct02407210-2015-04-02`, retrieved 2026-10-26)
- Start date: 2015-01 (registry gives no type) (ClinicalTrials.gov record NCT02407210, source copy `cardio:ctgov-nct02407210-2015-04-02`, retrieved 2026-10-26)
- Primary completion: 2015-10 (anticipated) (ClinicalTrials.gov record NCT02407210, source copy `cardio:ctgov-nct02407210-2015-04-02`, retrieved 2026-10-26)
- Completion: Not reported
- Countries: China (ClinicalTrials.gov record NCT02407210, source copy `cardio:ctgov-nct02407210-2015-04-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02407210-2015-04-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): azilsartan
- Intervention (Drug): Olmesartan medoxomil
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Olmesartan (`cardio:olmesartan`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: 87bf86f3d7cd3fd6c8140fe10fe8e44e7e3992da322e5d1305cb9226a216e8e9
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
